Sanofi: Sanofi & Regeneron's Dupixent receives Japanese marketing approval to treat patients with COPD
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Read full article »
Sanofi is a France-based healthcare firm that develops and markets pharmaceutical drugs and OTC medicines for the treatment of a range of diseases such as diabetes and cancer.
Read more